Semaglutide – obesity



Click on the links below to view abstracts and posters presented at this congress. All copyright remains that of the copyright holder. This page will be available for a limited period after the congress.

Poster presentation 564 Wilding

A randomised, phase 2, placebo- and active-controlled dose-ranging study of semaglutide for treatment of obesity in subjects without diabetes

  View PDF